Basal-like HR + /HER2- breast cancers show higher tumor-infiltrating lymphocytes and immune signatures with potential therapeutic implications

Abstract Hormone receptor-positive (HR + )/HER2-negative (HER2 − ) early breast cancers (BCs) are typically considered immunologically cold. However, combining immune checkpoint inhibitors (ICIs) with chemotherapy has shown to improve pathological complete response (pCR) in high-risk patients. Under...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Gaia Griguolo, Michele Bottosso, Laia Paré, Federica Miglietta, Daniele Giulio Generali, Antonino Musolino, Simon Spazzapan, Grazia Maria Vernaci, Tommaso Giarratano, Rocco Cappellesso, Silvio Bicciato, Federico Piacentini, Enrico Tagliafico, Katia Cagossi, Anna Tosi, Francesca Schiavi, Aleix Prat, Maria Vittoria Dieci, Valentina Guarneri
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Nature Portfolio 2025-12-01
Serie:	npj Breast Cancer
Länkar:	https://doi.org/10.1038/s41523-025-00886-w
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!